Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
Autor: | Hideyuki Satoh, Masafumi Arima, Takeshi Fukuda, Hiroyuki Masuda, Ryosuke Souma, Hajime Arifuku, Kenya Koyama, Kentaro Nakano, Shingo Tokita, Kumiya Sugiyama, Masamitsu Tatewaki, Hiroyoshi Watanabe, Yasutsugu Fukushima, Kazuhiro Kurasawa, Hirokuni Hirata, Yumeko Hayashi, Tomoshige Wakayama, Fumiya Fukushima |
---|---|
Rok vydání: | 2018 |
Předmět: |
Budesonide
medicine.medical_specialty Allergy Evening Biochemistry Symbicort maintenance and reliever therapy (SMART) immune system diseases Wheeze Internal medicine medicine Formoterol Asthma lcsh:RC705-779 Adjustable maintainable dose (AMD) business.industry Inhaler Research Organic Chemistry Peak expiratory flow (PEF) lcsh:Diseases of the respiratory system medicine.disease respiratory tract diseases Budesonide/formoterol medicine.symptom business medicine.drug |
Zdroj: | Asthma research and practice Asthma Research and Practice, Vol 4, Iss 1, Pp 1-8 (2018) |
ISSN: | 2054-7064 |
Popis: | Background The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient. Methods Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken. Results Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, p |
Databáze: | OpenAIRE |
Externí odkaz: |